List of Tobira Therapeutics patents | 8 results

Name	Description	Patent Applicant	Current Assignee	Patent Jurisdiction	Patent Number	Date of Patent
‌ US Patent 8741943 Bicyclic compound, production and use thereof	Patent 8741943 was granted and assigned to Tobira Therapeutics on June, 2014 by the United States Patent and Trademark Office.		Tobira Therapeutics	United States Patent and Trademark Office	8741943	June 3, 2014
‌ US Patent 10045968 Bicyclic compound, production and use thereof	Patent 10045968 was granted and assigned to Tobira Therapeutics on August, 2018 by the United States Patent and Trademark Office.	Tobira Therapeutics	Tobira Therapeutics	United States Patent and Trademark Office	10045968	August 14, 2018
‌ US Patent 8183273 Bicyclic compound, production and use thereof	Patent 8183273 was granted and assigned to Tobira Therapeutics on May, 2012 by the United States Patent and Trademark Office.		Tobira Therapeutics	United States Patent and Trademark Office	8183273	May 22, 2012
‌ US Patent 8362058 Bicyclic compound, production and use thereof	Patent 8362058 was granted and assigned to Tobira Therapeutics on January, 2013 by the United States Patent and Trademark Office.		Tobira Therapeutics	United States Patent and Trademark Office	8362058	January 29, 2013
‌ US Patent 9688666 Lamivudine salts	Patent 9688666 was granted and assigned to Tobira Therapeutics on June, 2017 by the United States Patent and Trademark Office.	Tobira Therapeutics	Tobira Therapeutics	United States Patent and Trademark Office	9688666	June 27, 2017
‌ US Patent 10407411 Purified cenicriviroc and purified intermediates for making cenicriviroc	Patent 10407411 was granted and assigned to Tobira Therapeutics on September, 2019 by the United States Patent and Trademark Office.	Tobira Therapeutics	Tobira Therapeutics	United States Patent and Trademark Office	10407411	September 10, 2019
‌ US Patent 10301287 Solid forms of cenicriviroc mesylate and processes of making solid forms of cenicriviroc mesylate	Patent 10301287 was granted and assigned to Tobira Therapeutics on May, 2019 by the United States Patent and Trademark Office.	Tobira Therapeutics	Tobira Therapeutics	United States Patent and Trademark Office	10301287	May 28, 2019
‌ US Patent 10526349 Process of making cenicriviroc and related analogs	Patent 10526349 was granted and assigned to Tobira Therapeutics on January, 2020 by the United States Patent and Trademark Office.	Tobira Therapeutics	Tobira Therapeutics	United States Patent and Trademark Office	10526349	January 7, 2020